À PROPOS DE CE PODCAST 🔗

Animateurs :
Fréquence de mise à jour:
every 40 days
Durée audio moyenne:
43 minutes
Entretiens avec des invités
A des sponsors
Podcast vidéo
Anglais
États-Unis
107 épisodes
depuis 16 décembre 2017
episodic

DERNIER ÉPISODE 🔗

In this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman. Stephen Spellman is Vice President and Senior Scientific Director at Be The Match and the Center for International Blood & Marrow Transplant Research (CIBMTR). Hofland and Spellman talk about the outcomes of a stu…

RECHERCHER LES ÉPISODES PASSÉS

Rechercher les épisodes précédents de The Onco'Zine Brief.

ÉPISODES PRÉCÉDENTS

In a new episode of The Onco’Zine Brief, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President and Chief Executive Officer of SonALAsense.SonALAsense was founded to create hope in the face of des…
In a new episode of The Onco’Zine Brief, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®.Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to…
In a new episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia.Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called P…
In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer.First, Hofland talks with Christopher Heery, MD.Dr Heery is a board-certified medical oncologi…
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells. Antibody-drug conjugates consist…
In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing…
In the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match. In the program today Hofla…
In this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to t…
Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. …
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de Peter Hofland, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.